nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A single administration of hIL-7-hyFc induces long-lasting T-cell expansion with maintained effector functions
|
Kim, Sojeong |
|
|
6 |
23 |
p. 6093-6107 |
artikel |
2 |
A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma
|
Thieblemont, Catherine |
|
|
6 |
23 |
p. 5995-6004 |
artikel |
3 |
Ayuk FA, Berger C, Badbaran A, et al. Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting. Blood Adv. 2021;5(11):2523-2527.
|
|
|
|
6 |
23 |
p. 6075 |
artikel |
4 |
C5 inhibition allows continued antineoplastic therapy in cancer- and chemotherapy-associated thrombotic microangiopathy
|
Shah, Hridaya |
|
|
6 |
23 |
p. 6071-6074 |
artikel |
5 |
D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study
|
Palareti, Gualtiero |
|
|
6 |
23 |
p. 6005-6015 |
artikel |
6 |
Editorial Board
|
|
|
|
6 |
23 |
p. i |
artikel |
7 |
Front Matter
|
|
|
|
6 |
23 |
p. ii |
artikel |
8 |
GATA1 controls numbers of hematopoietic progenitors and their response to autoimmune neuroinflammation
|
Hwang, Daniel |
|
|
6 |
23 |
p. 5980-5994 |
artikel |
9 |
Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL
|
Abramson, Jeremy S. |
|
|
6 |
23 |
p. 5969-5979 |
artikel |
10 |
Hematopoietic stem cell transplant for Hurler syndrome: does using bone marrow or umbilical cord blood make a difference?
|
Orchard, Paul J. |
|
|
6 |
23 |
p. 6023-6027 |
artikel |
11 |
Identification and characterization of RBM12 as a novel regulator of fetal hemoglobin expression
|
Wakabayashi, Aoi |
|
|
6 |
23 |
p. 5956-5968 |
artikel |
12 |
Is donor-recipient sex associated with transfusion-related outcomes in critically ill patients?
|
Wood, Henry |
|
|
6 |
23 |
p. 6076-6077 |
artikel |
13 |
Narkhede M, Goyal G, Shea L, et al. Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma. Blood Adv. 2022; 6(14):4122-4131.
|
|
|
|
6 |
23 |
p. 6039 |
artikel |
14 |
Production and nonclinical evaluation of an autologous iPSC–derived platelet product for the iPLAT1 clinical trial
|
Sugimoto, Naoshi |
|
|
6 |
23 |
p. 6056-6069 |
artikel |
15 |
PUM1 mediates the posttranscriptional regulation of human fetal hemoglobin
|
Elagooz, Reem |
|
|
6 |
23 |
p. 6016-6022 |
artikel |
16 |
Recurrent switch 2 domain RAC2 mutations in intravascular large B-cell lymphoma
|
Kodgule, Rohan |
|
|
6 |
23 |
p. 6051-6055 |
artikel |
17 |
RUNX1 deficiency cooperates with SRSF2 mutation to induce multilineage hematopoietic defects characteristic of MDS
|
Huang, Yi-Jou |
|
|
6 |
23 |
p. 6078-6092 |
artikel |
18 |
Temporal in vivo platelet labeling in mice reveals age-dependent receptor expression and conservation of specific mRNAs
|
Armstrong, Paul C. |
|
|
6 |
23 |
p. 6028-6038 |
artikel |
19 |
The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes
|
Faruqi, Aiman J. |
|
|
6 |
23 |
p. 6040-6050 |
artikel |
20 |
Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19
|
Ripoll, Juan G. |
|
|
6 |
23 |
p. 5951-5955 |
artikel |
21 |
Yes, donor-recipient sex is associated with transfusion-related outcomes in critically ill patients
|
Alshalani, Abdulrahman |
|
|
6 |
23 |
p. 6070 |
artikel |